2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.

The China bioventure sector is poised to set a record for initial public offerings and fundraising, but one therapeutic area is taking a surprise lead - immunology.

US high court agrees to hear case that could impact hundreds of patent decisions by PTAB; damage caused by continuing uncertainty ‘cannot be overstated,’ New York IP law association says.

Following the failure of PledOx, Pledpharma is joining forces with Rare Thyroid Therapeutics to target orphan treatments, initially focusing on the latter's investigational therapy for MCT8 deficiency.